By Daniel Akselrod · July 2026

Intake Forms for Substance Abuse Counseling: A Complete Guide for Addiction Treatment Providers

No area of clinical practice carries higher documentation stakes than substance abuse and addiction counseling. The intake process for a new client entering substance use disorder treatment is not merely an administrative formality — it is a clinical assessment, a legal safeguard, a regulatory compliance event, and often the first moment of genuine human connection in what may be a court-ordered, family-pressured, or crisis-driven entry into care. Get it wrong, and you risk misplacing a client on the continuum of care, violating federal confidentiality protections that are stricter than HIPAA, or missing a co-occurring condition that will derail treatment within the first two weeks.

This guide covers every section that a substance abuse counseling intake form should include, why each one matters from both a clinical and compliance perspective, and how to structure the documentation so that it protects the client, the counselor, and the program.

Why Substance Abuse Intake Forms Are Different

Before getting into the sections themselves, it is worth understanding why addiction treatment intake forms carry unique requirements that other behavioral health practices do not face.

First, substance use disorder records are governed by 42 CFR Part 2, a federal regulation that imposes confidentiality protections beyond what HIPAA requires. Under Part 2, a program cannot even acknowledge that a person is a patient without the individual's written consent. This means the intake form must include a consent architecture that most mental health or medical practices never think about.

Second, addiction treatment spans a wider continuum of care than almost any other clinical specialty. A single intake may need to determine whether the client belongs in medical detoxification, residential treatment, intensive outpatient, standard outpatient, or medication-assisted treatment — and the clinical and insurance implications of that placement decision are enormous. The ASAM Criteria (American Society of Addiction Medicine) provides the framework, but the intake form is where you collect the data that drives the placement.

Third, a significant percentage of clients entering substance abuse treatment are doing so under some form of external pressure — a court order, a child protective services mandate, a professional licensing board requirement, or an employer's last-chance agreement. These clients bring legal documentation that must be integrated into the intake process, and the treatment program takes on reporting obligations that require their own consent forms and tracking mechanisms.

Fourth, the medical acuity at intake can be high. Clients may present in active withdrawal, with overdose histories, with infectious disease exposure, or with medication regimens (methadone, buprenorphine, naltrexone) that require immediate coordination with prescribers. The intake form needs to capture enough medical information to triage safely.

Substance Use History and Pattern Documentation

The substance use history is the clinical core of the addiction intake form, and it needs to be substantially more detailed than the substance use screening section on a general mental health intake. This is not a "do you drink?" checkbox — this is a comprehensive inventory of the client's relationship with every substance they have used, organized in a way that reveals patterns, progression, and current severity.

Structured Substance-by-Substance Inventory

The most effective format is a grid or table that lists each substance category and captures, for each one: age of first use, age of regular use, route of administration (oral, intranasal, intravenous, smoked, sublingual), frequency of current use, quantity per use episode, date of last use, and whether the client has ever experienced withdrawal symptoms from that substance.

The substance categories should include at minimum: alcohol, cannabis, cocaine/crack, heroin, prescription opioids (specify), methamphetamine/amphetamines, benzodiazepines (specify), barbiturates, hallucinogens (LSD, psilocybin, MDMA), inhalants, synthetic cannabinoids, fentanyl (listed separately from other opioids given its prevalence and lethality), nicotine/tobacco, caffeine, and an open field for any substance not listed.

Two details that many intake forms miss and should not: route of administration and fentanyl as a separate line item. Route matters because intravenous use carries infectious disease risk (hepatitis B, hepatitis C, HIV) that triggers additional screening requirements, and because it is a marker of severity that affects level-of-care determination. Fentanyl deserves its own line because clients who believe they are using heroin, cocaine, or counterfeit pills may be unknowingly using fentanyl, and the withdrawal profile, overdose risk, and medication-assisted treatment protocol differ significantly.

Validated Screening Instruments

In addition to the substance-by-substance inventory, many programs embed one or more validated screening tools directly into the intake form or append them as scored addenda. The most commonly used instruments include:

The choice of screening instrument matters less than the consistency with which it is used. Pick one or two, embed them into the intake workflow, and score them every time. A scored AUDIT or DAST at intake gives you a baseline against which to measure treatment progress — and it gives payers a quantifiable justification for the level of care you are recommending.

42 CFR Part 2 Confidentiality: What Your Intake Form Must Include

If you run a substance use disorder treatment program — or even if you are a solo practitioner who holds yourself out as providing substance abuse diagnosis, treatment, or referral — you are almost certainly a "Part 2 program" subject to 42 CFR Part 2. This regulation, originally enacted in the 1970s to encourage people to seek addiction treatment without fear that their records would be used against them in criminal proceedings, imposes confidentiality requirements that go substantially beyond HIPAA.

Key Part 2 Requirements That Affect the Intake Form

Consent Form Architecture at Intake

At a minimum, the intake packet for a Part 2 program should include:

The practical implication is that the consent section of a substance abuse intake form is often three to four pages long — substantially longer than the consent section for a general therapy practice. This is not overlawyering. It is a federal requirement, and programs that cut corners on Part 2 consent face real regulatory exposure.

ASAM Criteria and Level of Care Determination

The ASAM Criteria is the national standard for matching clients to appropriate levels of addiction treatment. Your intake form needs to collect sufficient data across all six ASAM dimensions to support a defensible placement decision:

The intake form does not need to replicate the full ASAM assessment — that is the clinician's job in the biopsychosocial assessment that follows — but it needs to capture enough self-reported data across all six dimensions that the clinician can begin forming a placement recommendation before the first face-to-face assessment concludes. Failure to document ASAM-aligned data is the single most common reason that insurance companies deny authorization for higher levels of care.

Detoxification Screening and Medical Clearance

Clients who present for substance abuse treatment may need medical detoxification before they can safely participate in psychosocial treatment. The intake form must screen for withdrawal risk factors that determine whether the client needs medical monitoring during the detoxification period:

The intake form should also include a medical history section sufficient for medical clearance: current medications, known allergies, chronic conditions (liver disease, cardiovascular conditions, diabetes, seizure disorders, HIV/hepatitis status), current pregnancy or possibility of pregnancy, and date of last physical examination.

Co-Occurring Mental Health Disorder Assessment (Dual Diagnosis)

The co-occurrence of substance use disorders and mental health disorders is the rule, not the exception. Research consistently shows that approximately half of individuals with a substance use disorder also meet criteria for at least one co-occurring mental health condition, and the actual rate in treatment-seeking populations is likely higher. Depression, anxiety disorders, PTSD, bipolar disorder, ADHD, and personality disorders are the most common co-occurring conditions in substance abuse treatment settings.

The intake form needs to screen for co-occurring disorders with enough specificity to guide initial treatment planning. A single checkbox that says "mental health history: yes/no" is inadequate. Instead, include:

The clinical rationale for robust dual-diagnosis screening at intake is straightforward: if you treat the substance use disorder without addressing the underlying depression, PTSD, or anxiety, the client will relapse. And if you refer the client to a separate mental health provider without communicating the substance use history — which requires Part 2-compliant consent — the mental health provider is working blind. The intake form is where integrated treatment begins.

Medication-Assisted Treatment (MAT) Documentation

Medication-assisted treatment — the use of FDA-approved medications in combination with counseling and behavioral therapies — is the evidence-based standard of care for opioid use disorder and alcohol use disorder. The three primary MAT medications each carry their own intake documentation requirements:

Buprenorphine (Suboxone, Sublocade, Zubsolv)

If your program prescribes buprenorphine for opioid use disorder, the intake form needs to document: the client's opioid use history with sufficient detail to confirm an opioid use disorder diagnosis, current opioid tolerance level (which affects induction dosing), time since last opioid use (premature buprenorphine induction can precipitate withdrawal), history of prior buprenorphine treatment and reason for discontinuation if applicable, history of buprenorphine diversion or misuse, and the client's willingness to participate in counseling alongside medication.

Since the elimination of the X-waiver requirement in 2023, any DEA-registered practitioner with a Schedule III authority can prescribe buprenorphine for opioid use disorder. This expanded access means more programs are incorporating buprenorphine into their service offerings, and the intake form must be updated to capture the clinical data that supports safe prescribing.

Methadone

Methadone for opioid use disorder can only be dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs). OTP intake requirements are governed by 42 CFR Part 8 in addition to Part 2, and include: documentation of at least one year of opioid addiction (with exceptions for pregnant patients, recently incarcerated individuals, and patients previously treated with methadone), a physical examination within the past 30 days, tuberculosis screening, and pregnancy testing for individuals of childbearing potential. The intake form for an OTP is among the most heavily regulated in healthcare.

Naltrexone (Vivitrol)

Naltrexone blocks opioid receptors and is used for both opioid use disorder and alcohol use disorder. The critical intake documentation point for naltrexone is confirming that the client has been opioid-free for a minimum of 7-10 days (for short-acting opioids) or 10-14 days (for long-acting opioids like methadone). Administering naltrexone to a client with opioids in their system will precipitate severe withdrawal. The intake form must document the date and time of last opioid use, and many programs require a naloxone challenge test or urine drug screen confirmation before naltrexone initiation.

For all MAT medications, the intake form should also capture: informed consent specific to the medication (risks, benefits, alternatives, expected duration of treatment), agreement to comply with drug testing requirements, agreement to participate in counseling as a condition of receiving medication, and authorization to coordinate care with other prescribers.

Court-Ordered and Mandated Treatment Intake

A substantial portion of clients entering substance abuse treatment arrive under some form of legal mandate. The intake form must accommodate these clients with additional documentation sections that voluntary clients do not need:

The critical practice point for mandated clients is that treatment motivation is often external at intake — the client is there because they have to be, not because they want to be. The intake form cannot change this, but it can document the client's stage of change accurately, capture the legal requirements so the treatment team knows exactly what compliance looks like, and create a record that protects the program if the client later disputes what was communicated at intake.

Relapse History and Trigger Identification

For clients who have prior treatment experience — which is the majority in most substance abuse treatment settings — the relapse history section of the intake form provides some of the most clinically valuable data available at the start of treatment.

Clients who have been through treatment multiple times often experience shame about their relapse history. The intake form should frame these questions in a way that communicates that relapse is a clinical data point — not a moral failure — and that understanding the pattern is the foundation for building a more effective plan this time.

Social Support Network and Sober Living Assessment

ASAM Dimension 6 — Recovery/Living Environment — is frequently the dimension that makes or breaks treatment success, and it is the dimension most often underassessed at intake. The intake form should capture:

The sober living assessment is especially critical for clients transitioning from residential to outpatient levels of care, or for clients whose home environment was a primary contributor to their substance use. Documenting these factors at intake ensures that discharge planning begins on day one — not in the last week of treatment when housing and support gaps are suddenly urgent.

Drug Testing Consent and Chain of Custody Documentation

Drug testing is a standard component of substance abuse treatment, and the intake form must establish the consent and procedural framework for it at the outset. This section should cover:

For Part 2-covered programs, drug test results are protected substance use records. Disclosure of results to courts, probation officers, employers, or other outside parties requires the same Part 2-compliant written consent discussed earlier. The drug testing consent form and the Part 2 disclosure consent form should be cross-referenced at intake so the client understands the connection between consenting to drug testing and consenting to the disclosure of results.

Insurance Verification and Parity Compliance

Insurance verification at intake is a financial necessity, but in substance abuse treatment it also intersects with the Mental Health Parity and Addiction Equity Act (MHPAEA). This federal law requires that insurance plans offering mental health and substance use disorder benefits provide those benefits at parity with medical/surgical benefits — meaning the same deductibles, copays, visit limits, prior authorization requirements, and medical necessity criteria.

The intake form should capture:

Insurance verification is particularly important in substance abuse treatment because the authorization process is often iterative — payers may authorize an initial period at a given level of care and then require concurrent review for continued stay. The intake form establishes the baseline authorization, and the clinical documentation from that point forward supports each subsequent authorization request.

Family Involvement and Collateral Contact Consent

Substance use disorders affect families, and effective treatment often involves family members in some capacity — family therapy sessions, family education groups, multi-family groups, or at minimum communication with family members about the client's treatment progress. Under 42 CFR Part 2, none of this can happen without the client's written consent.

The intake form should include:

The family section of the intake form often reveals the relational dynamics that are sustaining the addiction. A client who lists no family contacts, or who refuses consent for any family communication, is communicating something clinically important — either that the family relationships are so damaged that contact would be harmful, or that the client is hiding the extent of their substance use from family members. Either way, it becomes part of the treatment picture.

Overdose History and Naloxone Access

With opioid overdose deaths remaining a leading cause of preventable death in the United States, every substance abuse intake form should include a dedicated overdose history and naloxone access section. This is not optional — it is a clinical safety imperative.

The intake form should also capture the client's overdose safety plan — whether they use alone, whether someone knows when they are using, whether they have access to fentanyl test strips, and whether they are willing to use naloxone or have someone available who can administer it. For clients who are not yet ready to commit to abstinence, this harm reduction information may be the most important safety data collected at intake.

Additional Sections for Comprehensive Documentation

Beyond the core sections above, a thorough substance abuse intake form may also include:

Structuring the Intake for Clinical Utility

A substance abuse intake form that covers all of the above will be a substantial document. The question is not whether to include these sections — they are all clinically and regulatory necessary — but how to organize them so the form is usable for both the client filling it out and the clinician reviewing it.

Several structural principles make the difference between an intake form that gets completed thoroughly and one that gets rushed through or skipped:

Putting It All Together

A well-designed substance abuse counseling intake form is a comprehensive clinical document that typically runs 10 to 16 pages when it includes all necessary sections and consent forms. That length is not a sign of overengineering — it is a reflection of the clinical complexity, regulatory requirements, and legal considerations that are unique to addiction treatment.

Every question on the form should earn its place by serving at least one of three purposes: informing the clinical assessment and treatment plan, satisfying a federal or state regulatory requirement, or protecting the client and the program in the event of a dispute, audit, or adverse outcome. Questions that do not meet any of these tests should be removed — but in substance abuse treatment, the list of questions that genuinely matter is long.

The intake form is also the first message a client receives about what treatment will be like. A form that is thorough, well-organized, and written in respectful language communicates that this program takes the work seriously and treats clients as whole people with complex lives — not as a diagnosis walking through the door. In addiction treatment, where trust is hard-won and easily lost, that first impression matters.

Professional intake forms for substance abuse counseling — ready to use

Fillable PDF intake form and client questionnaire covering substance use history, 42 CFR Part 2 compliance, ASAM level of care, MAT documentation, dual diagnosis screening, court-ordered treatment, drug testing consent, and relapse prevention.

Browse All Forms View Bundles